Can you really boost GLP-1 naturally? What the science says

What did @briannahealth actually say?

The creator claims GLP-1 receptor agonists cause dysesthesia, which she describes as nerve damage that "interferes with brain and neural signaling long term." She then connects this to Alzheimer's, dementia, and Parkinson's disease. She also warns that many drugs available in Canada lack regulatory approval, and suggests fiber, fat, and protein intake can naturally raise GLP-1 instead.

To be clear about what she's arguing: a reported side effect in clinical trials becomes, in her telling, evidence of irreversible nervous system damage that will cause neurodegenerative disease. That's a significant leap. She also mispronounces all three drug names, calling them "retitutide," "semaglotide," and "chryseptide," which is a minor issue, but it does suggest a surface-level familiarity with the medications she's warning against. The regulatory concerns about unapproved compounded drugs in Canada are the strongest part of her argument and actually have some basis in recent Health Canada enforcement activity.

Does the science back this up?

Dysesthesia has appeared in post-marketing surveillance and some trial data for GLP-1 agonists, but the leap from a reported symptom to "nervous system damage" causing dementia is not supported by current evidence. In fact, the research trend runs the opposite direction.

A 2024 analysis published in Alzheimer's and Dementia (Norgaard et al., 2024) found semaglutide use was associated with a significantly reduced risk of Alzheimer's disease in patients with type 2 diabetes, not an increased risk. Similarly, a large observational study in JAMA Neurology (Wium-Andersen et al., 2023) found GLP-1 receptor agonist users had lower rates of dementia diagnosis compared to matched controls. The neurological story for these drugs is complicated, but the weight of current evidence does not support the claim that they accelerate cognitive decline. If anything, the opposite hypothesis is being actively studied. Dysesthesia as a reported adverse event exists, but it is not classified as confirmed nerve damage in regulatory communications, and attributing it to long-term neurodegeneration is speculation dressed up as established fact.

What did they get wrong (or right)?

She got several things meaningfully wrong. The claim that dysesthesia "confirms" experts have been warning about neural damage misrepresents both the term and the evidence. Dysesthesia is an abnormal sensation, not a confirmed marker of irreversible nerve damage in this context. Her direct connection, "uncheck nervous system damage long term means Alzheimer's, dementia, Parkinson's," is not supported by clinical data and contradicts the direction of current research.

She also conflates compounded, unapproved GLP-1 products with brand-name regulated medications. The safety concerns are real for compounded versions, but applying them equally to approved semaglutide or tirzepatide is misleading. The statement about Health Canada busts for illegal sellers is accurate. Health Canada did issue advisories and enforcement actions in 2023 and 2024 regarding unauthorized GLP-1 products.

On the natural GLP-1 angle: eating protein, fat, and fiber does stimulate endogenous GLP-1 secretion. That's real physiology (Reimann et al., 2021, Diabetologia). But endogenous release after a meal and pharmacological GLP-1 receptor agonism are not equivalent interventions, particularly for people with type 2 diabetes or significant obesity. She is right that food choices matter, but framing them as alternatives to medication is a clinical decision, not a lifestyle tip.

What should you actually know?

If you're taking or considering a GLP-1 receptor agonist, the real safety conversation is more nuanced than this video suggests. Dysesthesia has been reported, particularly at higher doses of newer agents like retatrutide. That's worth knowing. But current evidence does not support the idea that these drugs cause dementia or Parkinson's disease. Some research suggests they may actually be protective against neurodegeneration, though that evidence is preliminary.

The regulatory warning about compounded and unapproved GLP-1 products is legitimate and worth taking seriously. If you're sourcing these medications outside of a licensed pharmacy or telehealth provider without Health Canada or FDA oversight, you have no assurance of dose accuracy or ingredient safety. That is a real risk, separate from the approved drugs.

• Ask your prescriber specifically about dysesthesia symptoms at higher doses and what to watch for.
• Confirm your medication is dispensed through a licensed, regulated pharmacy.
• Do not interpret this video as evidence that GLP-1 medications cause dementia. The current literature does not support that claim.
• Dietary changes that support GLP-1 secretion are beneficial regardless of medication status, but are not a proven substitute for pharmacotherapy in clinical obesity or type 2 diabetes.

Bottom line

This video takes a real but limited adverse event signal, dysesthesia, and inflates it into a narrative about brain damage and neurodegenerative disease that is not supported by evidence. The regulatory concerns about unregulated compounded drugs are legitimate. The neurodegenerative doom scenario is not. When someone ends a medical warning with "Russian roulette" and then offers to DM you for one-on-one help, it's worth pausing on that business model.